Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
Wen Wen, Chen Chen, Jiake Tang, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 516-523
Open Access | Times Cited: 394
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, et al.
The Lancet (2022) Vol. 401, Iss. 10373, pp. 281-293
Open Access | Times Cited: 316
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Calvin J. Gordon, Egor P. Tchesnokov, Raymond F. Schinazi, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 1, pp. 100770-100770
Open Access | Times Cited: 258
Molnupiravir in COVID-19: A systematic review of literature
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 6, pp. 102329-102329
Open Access | Times Cited: 212
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, et al.
EBioMedicine (2021) Vol. 72, pp. 103595-103595
Open Access | Times Cited: 130
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, et al.
Nature (2023) Vol. 623, Iss. 7987, pp. 594-600
Open Access | Times Cited: 114
Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 110
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye Khoo, Richard J. Fitzgerald, Tom Fletcher, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 12, pp. 3286-3295
Open Access | Times Cited: 104
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Advances and gaps in SARS-CoV-2 infection models
César Muñoz‐Fontela, Lina Widerspick, Randy A. Albrecht, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 1, pp. e1010161-e1010161
Open Access | Times Cited: 77
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Teresa I. Ng, Ivan Correia, Jane Seagal, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 961-961
Open Access | Times Cited: 77
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 679
Open Access | Times Cited: 75
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Seyed Mohammad Reza Hashemian, Mohammad Hossein Pourhanifeh, Michael R. Hamblin, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112517-112517
Open Access | Times Cited: 70
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva
Alieu Amara, Sujan Dilly Penchala, Laura Else, et al.
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 206, pp. 114356-114356
Open Access | Times Cited: 64
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
Sri Masyeni, Muhammad Iqhrammullah, Andri Frediansyah, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3006-3016
Open Access | Times Cited: 62
Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance
Sonali Chaturvedi, Gustavo Vasen, Michael Pablo, et al.
Cell (2021) Vol. 184, Iss. 25, pp. 6022-6036.e18
Open Access | Times Cited: 57
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Luis Menéndez‐Arias
Viruses (2022) Vol. 14, Iss. 4, pp. 841-841
Open Access | Times Cited: 42
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
Carolin M. Lieber, Robert M. Cox, Julien Sourimant, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Computational Analysis of Molnupiravir
Artem V. Sharov, Tatyana M. Burkhanova, Tuğba Taşkın‐Tok, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1508-1508
Open Access | Times Cited: 40
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
Kyle Rosenke, Atsushi Okumura, Matthew Lewis, et al.
JCI Insight (2022) Vol. 7, Iss. 13
Open Access | Times Cited: 37
Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 26
An iron–sulfur cluster in the zinc-binding domain of the SARS-CoV-2 helicase modulates its RNA-binding and -unwinding activities
Nunziata Maio, Md Kausar Raza, Yan Li, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 33
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top